Trading, Llc Ronin Net Worth

What's Trading Ronin's mailing address?

Trading's mailing address filed with the SEC is 350 N. ORLEANS STREET, 2N, , CHICAGO, IL, 60654.

Insiders trading at Xencor Inc

Over the last 11 years, insiders at Xencor Inc have traded over $93,804,287 worth of Xencor Inc stock and bought 1,139,502 units worth $15,515,932 . The most active insiders traders include Capital, Llcstafford John S..., John S Iii Stafford, and John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of $779,296. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth $536,500.

What does Xencor Inc do?

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product

Xencor Inc executives and stock owners

Xencor Inc executives and other stock owners filed with the SEC include:

• Bassil Dahiyat,
  President, Chief Executive Officer, Founder and Director
• Allen Yang,
  Senior Vice President, Chief Medical Officer
• Celia Eckert,
  Vice President, General Counsel, Corporate Secretary
• John Desjarlais,
  Senior Vice President, Research and Chief Scientific Officer
• John Kuch,
  Chief Financial Officer, Vice President
• Dr. Bassil I. Dahiyat Ph.D.,
  Co-Founder, CEO, Pres & Director
• Dr. Allen S. Yang M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Dr. John R. Desjarlais,
  Sr. VP of Research & Chief Scientific Officer
• Celia E. Eckert J.D.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• John J. Kuch,
  Sr. VP & CFO
• A. Bruce Montgomery,
  Lead Independent Director
• Dagmar Rosa-Bjorkeson,
  Independent Director
• Kurt Gustafson,
  Independent Director
• Yujiro Hata,
  Independent Director
• Richard Ranieri,
  Independent Director
• Kevin Gorman,
  Independent Director
• Ellen Feigal,
  Independent Director
• Julie Casciani,
  Executive Director - Human Resources
• Kirk Rosemark,
  Vice President, Regulatory Affairs and Quality Assurance
• Eric Kowack,
  Vice President, Program Leadership and Strategic Alliances
• Jeremy Grunstein,
  Vice President of Business Development
• Kirk Rosemark RAC,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Jennifer Sandoz,
  VP of HR
• Charles Liles,
  Associate Director and Head of Corp. Communications & Investor Relations
• John S Iii Ronin Capital, L...,
  
• Paul A Foster,
  Chief Medical Officer
• Barbara Klencke,
  Director
• Bruce L A Carter,
  Director
• Edgardo Jr Baracchini,
  Chief Business Officer
• Robert Jr. Baltera,
  Director
• Bart Jan Cornelissen,
  SR. VICE PRESIDENT & CFO
• John S Jr Stafford,
  10% owner
• Trading, Llc Ronin,
  10% owner
• Lloyd A Rowland,
  Sr. V.P. and General Counsel
• Atul Saran,
  Director
• Harold R Werner,
  Director
• Jonathan Fleming,
  Director
• John S Iii Stafford,
  10% owner
• Capital, Llcstafford John S...,
  
• Nancy Valente,
  EVP, Chief Development Officer